The Rise of MEDVi: A Phenomenal Entrepreneurial Tale
On April 2, The New York Times published a profile of Matthew Gallagher, a 41-year-old entrepreneur from Los Angeles who turned a mere $20,000 investment, alongside the help of his brother and various AI tools, into a telemedicine startup named MEDVi. This startup specializes in GLP-1 weight loss drugs, boasting a staggering turnover of $401 million in 2025 and projecting to reach $1.8 billion in 2026. While the story went viral, painting a picture of AI-driven success, important details about the company remain troubling.
The Illusion of Expertise: 800 Fake Doctors
To create MEDVi’s online presence, Gallagher engineered over 800 Facebook profiles posing as doctors. Names like Dr. Daniel Foster and Dr. Alistair Whitmore are not real; they are entirely fabricated profiles, complete with AI-generated photos. Targeting women aged 35 to 55 on Facebook, these profiles were designed to appear legitimate and trustworthy.
Misleading Media Associations
Interestingly, MEDVi’s official website boasts logos from well-established publications like Bloomberg and The Times, giving the impression of extensive media coverage. However, these claims are misleading as the company only had minimal advertising exposure in these outlets. The extent of this Facebook profiling operation, crucial to understanding MEDVi’s marketing strategy, was largely absent from The Times’ article.
Regulatory Concerns: FDA’s Warning
On February 20, 2026, the U.S. Food and Drug Administration (FDA) issued a warning letter to MEDVi, part of a broader warning to 30 telemedicine companies. This letter isn’t an outright accusation; rather, it serves as an advisory on two primary issues:
- Images of products suggested that MEDVi is a manufacturer, while it is merely a mediator that orders medications from third-party pharmacies.
- Claims that their compounded products have the “same active ingredient as Wegovy® and Ozempic®” imply FDA approval, which doesn’t apply to compounded medications.
Questionable Product Effectiveness
MEDVi includes compounded oral tirzepatide—a weight-loss product that does not exist in an FDA-approved form. Presenting it as both safe and effective is misleading, especially since no approved oral GLP-1 product requires controlled conditions for administration. The company essentially marketed a drug likely to be ineffective, even amid warnings from established pharmaceutical companies regarding these products.
Data Security Breach
In a shocking breach of privacy, MEDVi outsourced its medical infrastructure to OpenLoop Health. In January 2026, a cybercriminal accessed their systems, exposing the medical records of approximately 1.6 million patients. Personal data—including names, contact details, and medical information—was compromised, with Texas alone reporting at least 68,000 affected individuals.
Spam Marketing Lawsuit
Gallagher’s marketing methods have also come under legal scrutiny. MEDVi is currently facing a lawsuit in California for violating anti-spam laws. The company allegedly engaged in practices involving falsified information, spoofed domains, and techniques to bypass spam filters. Gallagher’s initial investment of $20,000 in software and marketing raises questions about how much of their growth stemmed from these questionable tactics.
A Success Story Overshadowed
While The New York Times presents a compelling narrative of AI-driven capitalism, the reality of MEDVi’s operations reveals significant ethical concerns. They achieved a jaw-dropping revenue of $401 million in 2025, but questions remain about the legitimacy of these sales. How much of this income came from consumers purchasing potentially ineffective medication, promoted through fictitious doctors, and facilitated by a data infrastructure that compromised their sensitive information?
In an age where AI reshapes industries, the MEDVi case exemplifies the intersection of innovation and ethics, posing a significant dilemma for the future of telemedicine and consumer protection.